Provided by Cary Miller
Cary Miller, who holds a Ph.D. in cellular, developmental, and molecular biology, assists leading pharmaceutical, biotechnology and medical device companies to navigate complex patent issues—primarily for drug candidates and FDA approved products. Recently, Cary represented Celgene (now a Bristol Myers Squibb company) in multiple Hatch-Waxman litigations involving the top-selling pharmaceuticals Revlimid®, Pomalyst® and Abraxane®. She has handled biosimilars litigation governed by the Biologics Price Competition and Innovation Act (BPCIA), and provides extensive counseling in that space. In the gene therapy sector, Cary represents plaintiff REGENXBIO in a patent lawsuit involving host cells for making DNA for gene therapy applications, and recently successfully defended REGENXBIO in a PGR challenging one of its gene therapy patents. She has successfully litigated patent cases through the U.S. and before the PTAB, Federal Circuit and Supreme Court. Cary leverages two decades of litigation experience to drive the development of cutting-edge patent portfolios with an eye towards thwarting litigation. Cary has significant experience involving patent term extension applications for drugs, biologics, and medical devices. She has drafted and prosecuted patents relating to breakthrough therapies in a number of areas, including antibodies and antibody-drug conjugates, cancer therapeutics and diagnostics, human embryonic stem cells, and drug delivery devices.
Cary Miller is frequently called upon to handle complex patent disputes, with particular expertise in Hatch-Waxman litigation. She counts a number of leading pharmaceutical companies among her clients.
"Cary is a very sophisticated attorney and a stellar business adviser for the pharma industry."